Overview

. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2. To evaluate the safety and prognostic imaging factors of regorofenib in advanced second-line therapy; 3, to explore whether it is necessary to increase the treatment of TACE in the second-line treatment of advanced HCC.

Eligibility

Inclusion Criteria:

        ( - ) After pathological / clinical diagnosis of hepatocellular carcinoma or radical
        resection of hepatocellular carcinoma; ( - ) CNLC Ⅲa Patients with intrahepatic recurrence
        before (including a); ( - ) Previous failure of first-line systemic treatment; ( - ) Age:
        18-75 years old; ( - ) Child-Pugh 7 points; ( - ) ECOG PS Grade 0-2; ( - ) At least one
        measurable lesion in the liver.
        Exclusion Criteria:
        ( - ) Known hepatobiliary tubular cell carcinoma and mixed cell carcinoma and fibrolamellar
        cell carcinoma; ( - ) Previous (within 5 years) or concurrent other incurable malignant
        tumors; ( - ) Having received local treatment, systemic chemotherapy, radiotherapy other
        than TACE during the first-line systemic treatment; ( - ) During the second-line systemic
        treatment, I also received local treatment, systemic chemotherapy, radiotherapy other than
        TACE; ( - ) Serious uncontrollable systemic and other systemic diseases, such as uremia,
        cardiovascular and cerebrovascular accidents; ( - ) Allergy to any drug included in the
        study; ( - ) Pregnant or lactating women;